Partnership Models
Customized global BD partnership solutions
-
Discovery Collaboration
Leveraging our proprietary platforms and deep scientific expertise to co-discover new medicines
-
Asset Licensing
Global partnerships to advance assets in our innovative pipeline globally
-
Investment or
Co-DevelopmentWe welcome flexible partnership models, including investment in, and co-development of, our innovative assets for global patients
Cases
-
×ALKGenSci partners with ALK, the Denmark-based global leader in allergy immunotherapy (AIT). Under the agreement, GenSci and ALK will work closely together to develop and commercialise ALK's AIT products in China; meanwhile, GenSci will obtain exclusive rights to distribute 3 AIT products developed by ALK in mainland China.
-
×TWiGenSci Singapore has recently reached a cooperation agreement with TWi Pharmaceuticals, Inc. (TWi), a leading pharmaceutical company, and obtained the exclusive distribution of Megaxia? (megestrol acetate oral suspension). Under this agreement, TWi authorizes GenSci Singapore as the sole distributor of Megaxia? in mainland China, Hong Kong, Macau, and Singapore, responsible for the marketing and promotion of this product. -
×YarrowYarrow secures exclusive ex-Greater China global rights to develop, manufacture and commercialize GenSci's proprietary TSHR antagonist antibody GenSci098 (YB-101). The deal totals USD 1.365B milestone payments, including a USD 120M upfront payment and near-term development milestones. It marks a key milestone for Chinese innovative assets gaining global recognition in thyroid disease, and will speed up the program's global progression.
Our Partners
成人成长激素不足（AGHD）, 成长激素不足（PGHD）, 特发性身段矮 。↖SS），成人成长激素不足（AGHD）, 成长激素不足（PGHD）, 特发性身段矮 。↖SS）
Collaborate to Advance Global, Patient-First Innovation.
-
Email
-
Phone
-
Address
No.299, Furonghua Road, Pudong, Shanghai